TY  - GEN
AU  - Ma,Brigette B Y
AU  - Lim,Wan-Teck
AU  - Goh,Boon-Cher
AU  - Hui,Edwin P
AU  - Lo,Kwok-Wai
AU  - Pettinger,Adam
AU  - Foster,Nathan R
AU  - Riess,Jonathan W
AU  - Agulnik,Mark
AU  - Chang,Alex Y C
AU  - Chopra,Akhil
AU  - Kish,Julie A
AU  - Chung,Christine H
AU  - Adkins,Douglas R
AU  - Cullen,Kevin J
AU  - Gitlitz,Barbara J
AU  - Lim,Dean W
AU  - To,Ka-Fai
AU  - Chan,K C Allen
AU  - Lo,Y M Dennis
AU  - King,Ann D
AU  - Erlichman,Charles
AU  - Yin,Jun
AU  - Costello,Brian A
AU  - Chan,Anthony T C
TI  - Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
SN  - 1527-7755
PY  - 2019///0726
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents, Immunological
KW  - therapeutic use
KW  - Biomarkers, Tumor
KW  - metabolism
KW  - Disease Progression
KW  - Female
KW  - HLA Antigens
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Nasopharyngeal Carcinoma
KW  - drug therapy
KW  - Neoplasm Recurrence, Local
KW  - Nivolumab
KW  - Programmed Cell Death 1 Receptor
KW  - Survival Rate
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2017.77.0388
ER  -